Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis

MLA

HAG Trombose, et al. Clinical Consequences of Off-Label Reduced Dosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432121901&authtype=sso&custid=ns315887.

APA

HAG Trombose, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Directie Raad van Bestuur, Joosten, L. P. T., van Maanen, R., van den Dries, C. J., Rutten, F. H., Hoes, A. W., Granger, C. B., Hemels, M. E. W., Geersing, G.-J., & van Doorn, S. (2023). Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.

Chicago

HAG Trombose, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Directie Raad van Bestuur, Linda P T Joosten, Rosanne van Maanen, et al. 2023. “Clinical Consequences of Off-Label Reduced Dosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432121901&authtype=sso&custid=ns315887.